Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix, discusses the company’s success with non-dilutive funding.

Ram May-Ron, Managing Partner of the FreeMind Group, Dongkyu “Theirry” Uh, President of Daewoong Innovation Holdings, and Ayal Ronen, Chief Business Officer of the FreeMind Group discuss our new venture capital fund, FreeMind Investments.

The NCI Small Business Programs: Supporting Cancer Start-Ups – Deepa Narayanan, Program Director, Small Business Innovation Research (SBIR) Development Center, National Cancer Institute

Funding Opportunities for Biomedical Product Development at NIDA – Victor Prikhodko, Senior Business Development Manager, National Institute on Drug Abuse

Non-Dilutive Funding Opportunities from the Defense Threat Reduction Agency – Dr. Ron Hann, Director, Chemical and Biological Technologies Department, DTRA

The NIAID SBIR/STTR Programs, Funding Opportunities, and Application Tips – Dr. Susan E. Old, Deputy Director, Division of Extramural Activity, NIAID

NIH and VC Funding; Growth Engines for the Life Science Industry; Exploring Similarities, Differences, and Overall Objectives. A panel discussion at the 14th Annual Non-Dilutive Funding Summit featuring: Ram May-Ron, Managing Partner, FreeMind Group | B. Christopher Kim, Managing Partner, Novatio Ventures | Dr. Matthew Portnoy, Director, Division of Special Programs – Office of Extramural Research, NIH

 

Tyler G. Merkeley, MS, MBA, PMP, Interim Director, DRIVe (Division of Research, Innovation, and Ventures), presents: From CARB-X to DRIVe: How We Are Building Novel Public Private Partnership with Non-Dilutive Funding to Foster Disruptive Innovation to Enhance National Health Security at the 14th Annual Non-Dilutive Funding Summit.

View slide deck